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Introduction: Idiopathic pulmonary fibrosis is a progressive diffuse parenchymal lung disorder of unknown etiology.
Mesenchymal stem cell (MSC)-based therapy is a novel approach with great therapeutic potential for the treatment of
lung diseases. Despite demonstration of MSC grafting, the populations of engrafted MSCs have been shown to decrease
dramatically 24 hours post-transplantation due to exposure to harsh microenvironments. Hypoxia is known to induce
expression of cytoprotective genes and also secretion of anti-inflammatory, anti-apoptotic and anti-fibrotic factors. Hypoxic
preconditioning is thought to enhance the therapeutic potency and duration of survival of engrafted MSCs. In this work,
we aimed to prolong the duration of survival of engrafted MSCs and to enhance the effectiveness of idiopathic
pulmonary fibrosis transplantation therapy by the use of hypoxia-preconditioned MSCs.
Methods: Hypoxic preconditioning was achieved in MSCs under an optimal hypoxic environment. The expression levels
of cytoprotective factors and their biological effects on damaged alveolar epithelial cells or transforming growth factor-beta
1-treated fibroblast cells were studied in co-culture experiments in vitro. Furthermore, hypoxia-preconditioned MSCs
(HP-MSCs) were intratracheally instilled into bleomycin-induced pulmonary fibrosis mice at day 3, and lung functions,
cellular, molecular and pathological changes were assessed at 7 and 21 days after bleomycin administration.
Results: The expression of genes for pro-survival, anti-apoptotic, anti-oxidant and growth factors was upregulated in MSCs
under hypoxic conditions. In transforming growth factor-beta 1-treated MRC-5 fibroblast cells, hypoxia-preconditioned MSCs
attenuated extracellular matrix production through paracrine effects. The pulmonary respiratory functions significantly
improved for up to 18 days of hypoxia-preconditioned MSC treatment. Expression of inflammatory factors and fibrotic
factor were all downregulated in the lung tissues of the hypoxia-preconditioned MSC-treated mice. Histopathologic
examination observed a significant amelioration of the lung fibrosis. Several LacZ-labeled MSCs were observed within the
lungs in the hypoxia-preconditioned MSC treatment groups at day 21, but no signals were detected in the normoxic MSC
group. Our data further demonstrated that upregulation of hepatocyte growth factor possibly played an important role in
mediating the therapeutic effects of transplanted hypoxia-preconditioned MSCs.
Conclusion: Transplantation of hypoxia-preconditioned MSCs exerted better therapeutic effects in bleomycin-induced
pulmonary fibrotic mice and enhanced the survival rate of engrafted MSCs, partially due to the upregulation of hepatocyte
growth factor.* Correspondence: kchong@mail.cgu.edu.tw
1Division of Biotechnology, Graduate Institute of Biomedical Sciences,
College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of
China
12Department of Medical Biotechnology and Laboratory Science, College of
Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of China
Full list of author information is available at the end of the article
© 2015 Lan et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lan et al. Stem Cell Research & Therapy  (2015) 6:97 Page 2 of 17Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and pro-
gressive form of interstitial lung disease characterized by
an intricate cytokine network and abnormal deposition of
mesenchymal cells [1,2]. To date, there are no effective
and approved treatments for IPF [3], making IPF the most
life-threatening idiopathic disease with a median survival
of about 3 years from initial diagnosis.
Mesenchymal stem cell (MSC)-based cell therapy is a po-
tential therapeutic approach for the treatment of various
lung diseases [4,5]. Several studies have demonstrated that
MSCs home to sites of lung injury, an event also associated
with reduced tissue damage, inhibited production of proin-
flammatory mediators, decreased extracellular matrix colla-
gen deposition, and generally contributed to tissue repair
[6,7]. In addition, MSCs secrete paracrine factors with anti-
inflammatory, anti-apoptotic and anti-fibrotic functions
[8,9]. Despite reported success, it was demonstrated that
the amount of engrafted MSCs decreased dramatically after
24 hours of transplantation due to exposure to toxic and
oxidative microenvironments [10]. Recent studies involving
overexpressing anti-oxidant [11,12] or anti-apoptotic genes
or growth factors in engrafted stem cells have shown im-
proved survival following transplantation [13]. In addition,
cells, tissues or whole animals may be preconditioned by
sub-lethal exposure to selected stresses to induce prior ex-
pression of cytoprotective genes before subsequent lethal
challenges [14]. Cellular preconditioning may include ex-
posure of cells to physiological stimuli such as hypoxia, heat
shock, small-molecule pharmacological agents, cytokines,
growth factors or biophysical stimuli. Alternatively, cellular
preconditioning may be achieved by genetic manipulation
by overexpression of anti-apoptotic proteins, chemokine re-
ceptors, growth factors or pro-survival genes prior to trans-
plantation [15-18].
Adopting appropriate preconditioning strategies may
provide a simple yet effective way of promoting survival
and regenerative properties, and also the tissue repair cap-
ability of transplanted cells in stem cell-based therapy [19].
Recent studies have also shown that short-term exposure
of MSCs to sub-lethal hypoxia before transplantation
enhances cell survival and downregulation of apoptosis-
related pathways [19,20]. Furthermore, hypoxic precondi-
tioning also induces the expression of pro-survival markers
[21], chemoattractants [22] and growth factors involved in
cell proliferation, anti-oxidation, anti-apoptosis and angio-
genesis [23] in MSCs. Hypoxic preconditioning and stem
cell transplantation have been extensively studied in a num-
ber of organs and tissues in relation to diseases to enhance
therapeutic effects; the studies have included ischemic dis-
eases such as stroke and myocardial infarction [19,24-26],
traumatic brain injuries [27], diabetes mellitus [28], inflam-
matory bowel disease [29], and acute kidney [22,30] and
liver injuries [31]. However, there have been no publishedstudies on using hypoxia-preconditioned MSCs (HP-MSCs)
in the treatment of pulmonary fibrosis.
In this work, we investigated if hypoxic preconditioning
of MSCs would lead to comprehensive regulation that
promotes cell survival, enhances cytoprotective and growth
factor action, and attenuates extracellular matrix (ECM)
production. These effects were anticipated to result in inhib-
ited inflammatory response, fibrotic factor production, and




Bleomycin sulfate from Streptomyces verticillus was ob-
tained from Sigma-Aldrich (St Louis, MO, USA). The c-
Met inhibitor PHA-665752 was purchased from Santa Cruz
Biotechnology, Inc. (Dallas, TX, USA).
Cell lines
MSCs were isolated from the bone marrow of C57BL/6 fe-
male mice. MSCs were purchased from Life Technologies
(GIBCO mouse C57BL/6 MSCs; Carlsbad, CA, USA) fol-
lowing the guidelines of Good Manufacturing Practices for
medical derivatives, Code of Federal Regulations Title 21
(21 CFR), Part 820 of the US Food and Drug Administra-
tion regulation. The female murine alveolar epithelial cell
line (MLE-12; CRL-2110) was purchased from American
Type Culture Collection (Manassas, VA, USA). Both cell
lines were maintained in Dulbecco’s modified Eagle’s
medium/Ham’s Nutrient Mixture F-12 (Life Technologies)
supplemented with 10% fetal bovine serum (Life Technolo-
gies), 2 mM L-glutamine (Life Technologies) and 1% peni-
cillin/streptomycin (Life Technologies). Human 14-week
male embryonal lung cell line (MRC-5; BCRC-60023) was
purchased from Bioresource Collection and Research
Center (Hsinchu, Taiwan). MRC-5 cells were maintained in
Eagle’s minimal essential medium (Life Technologies) sup-
plemented with 10% fetal bovine serum (Life Technologies)
and 1% penicillin/streptomycin (Life Technologies), and
were incubated at 37°C in a 5% CO2 incubator.
Viral production and viral transduction
Virus stocks were prepared by co-transfecting the pLenti6/
v5-GW/lacZ plasmid (Life Technologies) with three pack-
aging plasmids, pMDLg/pRRE, CMV-VSVG and RSV-Rev,
into 293 T cells following the method of Chen and col-
leagues [32]. The viral supernatants were harvested 36 to
48 hours later, filtered and centrifuged at 20,000 × g for 90
minutes. The viral titer was determined by the method of
end-point dilution through counting the number of in-
fected red cells at ×100 magnification under a fluorescence
microscope 96 hours after infection to 293 T cells. Titer in
transducing units was computed as follows: (TU)/mL =
(the numbers of red fluorescent cells) × (dilution factor)/
Lan et al. Stem Cell Research & Therapy  (2015) 6:97 Page 3 of 17(volume of virus solution). Titers of the viral particles were
quantified by HIV-quantification enzyme-linked immuno-
sorbent assay kit. MSCs were seeded in 12-well plates and
the cells were transduced with an equal ratio of viral parti-
cles of pLenti6/v5-GW/lacZ virus particle and the stably
transduced cells were designated as β-Gal-MSCs.
Hypoxic preconditioning
MSCs were grown to confluency and were changed to
fresh complete medium before hypoxia treatment using a
finely-controlled ProOx-C-chamber system (Biospherix,
Redfield, NY, USA) for 24 hours. The oxygen concentra-
tion in the chamber was maintained at 1.5% with a re-
sidual gas mixture composed of 5% carbon dioxide and
balanced nitrogen. Normoxia-treated MSCs used as a con-
trol were cultured in 95% atmospheric air and 5% CO2 for
24 hours. Conditioned medium was collected from MSCs
cultured in normoxic or hypoxic conditions.
Measurement of mitochondrial membrane potential
Mitochondrial membrane potential was assessed using a
sensitive fluorescent probe JC-10 (Enzo Life Sciences Inc.,
Farmingdale, NY, USA). MSCs were incubated with JC-10
(1 μM) at 37°C for 30 minutes. JC-10 is capable of select-
ively entering into mitochondria, and reversibly changes
its color from green (JC-10 monomeric form) to orange
(JC-10 aggregate form) as membrane potentials increase.
Both colors can be detected using flow cytometers (FACS-
Calibur; BD Biosciences, San Jose, CA, USA).
Mesenchymal stem cells and MRC-5 co-culture assay
MSCs were plated at a density of 1 × 105 cells/well and
MRC-5 cells were plated at a density of 2 × 105 cells/well in
transwells (BD Biosciences) and 6-well culture plates (BD
Biosciences), respectively, and the cells were cultured over-
night. MSCs were then treated with the indicated oxygen
concentrations in hypoxic treatment for 24 hours. MRC-5
cells were treated with or without 2.5 ng/mL transforming
growth factor (TGF)-β1 (Sino Biological Inc., Beijing,
China) for 24 hours. After removing the medium, hypoxia-
pretreated MSCs in transwells were co-cultured with the
MRC-5 cells for 24 hours. The MRC-5 cells were harvested
for detection of fibronectin mRNA expression level by
quantitative real-time RT-PCR.
PHA665752 treatment
MRC-5 cells were plated at a density of 2 × 105 cells/well in
6-well culture plates (BD Biosciences) and cells were treated
with or without indicated concentrations of PHA665752
(Sigma-Aldrich) and 2.5 ng/mLTGF-β1 (Sino Biological) for
24 hours. After removing the medium, hypoxia-pretreated
MSCs in transwells were co-cultured with the PHA665752-
treated MRC-5 cells for 24 hours. The MRC-5 cells wereharvested for detection of fibronectin mRNA expression
level by quantitative real-time RT-PCR.
Cell proliferation and viability test
MSCs were plated at a density of 5 × 104 cells/well in a
12-well culture plate (BD Biosciences) and incubated
overnight to allow adhesion. The cells were then treated
with the indicated concentrations of oxygen for 24
hours. The cells were detached by trypsinization and
were counted in triplicate using a Countess™ automated
cell counter (Life Technologies). Cell viability was mea-
sured using 0.4% (w/v) trypan-blue (Sigma-Aldrich) ex-
clusion and the Countess™ software.
Cell viability MTT assay
MLE-12 cells were plated at a density of 1 × 105 cells/well in
a 24-well culture plate (BD Biosciences) and were cultured
to confluency. The cells were treated with bleomycin (BLM;
13.5 μM) in the presence of normoxia-preconditioned MSC
(NP-MSC)- or HP-MSC-conditioned medium for 48 hours.
The cell viability was then detected using the MTT method
at a wavelength of 540 nm by VERSAMax spectrophotom-
etry (Molecular Devices, Sunnyvale, CA, USA) as previous
described [33].
Short hairpin RNA and transient transfection
The hepatocyte growth factor (HGF) short hairpin RNA
(shRNA) clone (TRCN0000336131; GGTAAAGGAGG-
CAGCTATAAA) targeted at the mouse HGF transcript
was purchased from the National RNAi Core Facility
(Academia Sinica, Taipei, Taiwan). MSCs were plated at
a density of 1 × 105 cells/well in a 24-well plate and were
transfected with 2.5 μg HGF shRNA plasmid premixed
with 2.5 μl Lipofactamine™ LTX (Life Technologies) for
24 hours. At the end of the incubation, MSCs were
exposed to hypoxia for 24 hours. Following hypoxic pre-
conditioning, cells were used in co-culture assays.
Annexin V/propidium iodide double-staining assay
At 1 hour post-H2O2 (Sigma-Aldrich) treatment (0.5, 1,
and 2 μM), cell viability of NP-MSCs and HP-MSCs were
detected by Annexin V/propidium iodide (PI) staining
(Strong Biotech Co., Taipei, Taiwan). Briefly, 1 × 105 cells
were labeled with 1 μL Annexin V and PI in a binding buf-
fer for 15 minutes. The cells were analyzed using a flow
cytometer (FACSCalibur; BD Biosciences). The percentage
of cell numbers in each quadrant was calculated using
CELLQUEST software (BD Biosciences).
RNA isolation and quantitative real-time RT-PCR
Total RNA was prepared from the cell lines and was
treated with DNase I (New England BioLabs, Ipswich, MA,
USA). RNAs were reverse transcribed into cDNAs at 42°C
for 60 minutes using Moloney Murine Leukemia Virus
































GAPDH Forward: AGAGACGGCC GCATCTTCTT
Reverse: CCGTTCACACCGACCTTCAC
BAX-2, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; CAT, catalase; Col III,
collagen type III; CTGF, connective tissue growth factor; EPOR, erythropoietin
receptor; HGF, hepatocyte growth factor; HIF-1α, hypoxia-inducible factor 1α;
HO-1, heme oxygenase-1; IL, interleukin; VEGF, vascular endothelial growth factor.
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(dT)-primed reverse transcription reaction, quantitative
real-time RT-PCR was performed using LightCycler 480
SyberGreen I Master Mix and LightCycler® 480 Instrument
(Roche, Mannheim, Germany) as previously described
[34]. Sequences of the mouse gene-specific primers used
and for the human fibronectin are listed in Table 1. For
normalization, the GADPH mRNA level of each RNA
preparation was determined. Relative gene expression was
determined by the ΔΔCt method, where Ct is threshold
cycle. The relative mRNA levels were normalized to the
mRNA level of the reference GADPH gene. The melting
curve of the amplification product was always checked to
ensure a single clean peak that represented good-quality
quantitative real-time RT-PCR data.
Western blot analysis
Total cellular proteins were isolated from cell lines by the
PRO-PREP™ Protein Extraction Solution (Intron Biotech-
nology, Kyonggi-do, Korea). Western blot analysis was
performed as described previously [35]. Briefly, 25 or 50 μg
total protein from cell lysates or conditioned media was
loaded onto each lane and the proteins were separated in
SDS-PAGE (Bio-Rad Laboratories, Hercules, CA, USA).
After electrophoresis, the resolved proteins were transferred
to PVDF membrane (Millipore, Billerica, MA, USA). The
membranes were blocked with 5% skimmed milk powder
(Anchor, Kowloon, Hong Kong) in phosphate-buffered sa-
line (PBS)-Tween (PBS containing 0.1% Tween-20 (both
Sigma-Aldrich)) for 1 hour and probed overnight with the
following antisera at appropriate dilutions: anti-heme oxy-
genase 1 (HO-1; MBL International, Woburn, MA, USA;
1:1,000), anti-fibronectin, anti-HGF, anti-vascular endothe-
lial growth factor (VEGF) and anti-interleukin (IL)-1β
(Santa Cruz Biotechnology; 1:1,000), primary antibodies de-
tecting pan-AKT or phospho-AKT S473 (Cell Signaling
Technology, Beverly, MA, USA; 1:2,000), and anti-β-actin
(Millipore; 1:10,000) antisera in PBS-Tween. Identification
of each protein was achieved with the Western Lighting
Plus Reagent (Perkin Elmer, Waltham, MA, USA) using an
appropriate horseradish peroxidase-conjugated secondary
antibody (Jackson Immuno Research Laboratories, West
Grove, PA, USA). Protein levels in the western blot analysis
were detected and quantified by the LAS-3000 chemilu-
minescence detection device (Fujifilm, Valhalla, NY, USA).
To adjust for loading differences, the optical density of each
protein was normalized to that of the β-actin band.
Animal model of bleomycin-induced lung fibrosis
Eight-week old male C57BL/6JNarl mice were purchased
from the National Laboratory Animal Center (Taipei,
Taiwan). The mice were maintained in an air-conditioned
animal facility under constant temperature and humidity
conditions with a 12:12 light-dark cycle and were allowedad libitum diet and drinking water. Mice were randomly
picked to different groups and there were at least six or
more mice in each group. All experimental procedures
were approved by the Institutional Animal Care and Use
Committee of the Chang Gung University. Bleomycin sul-
fate (Sigma-Aldrich) stock was prepared by dissolving in
sterile PBS at 10 mg/mL and storing in small aliquots at
4°C. Mice were anesthetized by isoflurane (Abbott Labora-
tories, Abbott Park, IL, USA) inhalation and BLM was in-
stilled intratracheally at 1.5 mg/kg body weight in 50 μL
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of either BLM or PBS on day 0. On day 3, mice were ran-
domly selected for intratracheal injection (5 × 105 cells in
50 μl PBS) of normoxia- or hypoxia-pretreated MSCs, or
just PBS. On day 4 and day 18 after stem cell transplant-
ation, animals were placed in the whole-body plethysmo-
graph tanks for analysis of pulmonary functions. At each
time point, the mice were sacrificed by an overdose of
2.5% avertin (Sigma-Aldrich).
Noninvasive measurement of pulmonary functions by
whole-body plethysmography
The baseline enhanced respiratory pause (Penh) in unre-
strained conscious mice was measured by whole-body pleth-
ysmography (Buxco Electronic Inc., Wilmington, NC, USA).
Mice were placed in the chamber and allowed to equilibrate
for approximately 10 minutes. According to the manufac-
turer’s instructions, Penh is calculated by the formula
Penh = (Te/Rt-1) × (PEF/PIF), where Te is expiratory time
(seconds); Rt is relaxation time (seconds), defined as the
time of “volume” decay to 35% of the total expiratory
pressure signal (area under the box pressure signal at ex-
piration); PEF is peak expiratory flow (ml/second); and
PIF is peak inspiratory flow (ml/second). Penh reflects
changes in the waveform of the box pressure signal during
both inspiration and expiration, and combines these
changes with the timing comparison of early and late ex-
piration during the animal’s spontaneous breathing. Penh
was measured for 3 minutes for each experiment.
Lung morphometry
Left lungs were fixed with 10% formalin (Macron Fine
Chemicals™, Avantor Performance Materials, Center Val-
ley, PA, USA) and were embedded in paraffin sections
before staining with hematoxylin and eosin (Sigma-Al-
drich) according to standard protocols. Briefly, 4-μm ser-
ial step sections were taken along the longitudinal axis
of the lobe. The fixed distance between the sections was
calculated to allow systematic sampling of 10 sections
across the whole lobe. The severity of lung fibrosis was
assessed by measuring the Masson’s trichrome staining
[36]. The Ashcroft score was used for quantitative histo-
logical analysis of fibrotic changes induced by BLM. Five
fields within each lung section were observed, and the
score of fibrosis ranged from 0 (normal lung) to 8 (total
fibrous obliteration of the field) [37].
Immunohistochemical staining of β-gal
Immunohistochemistry was performed to evaluate engraft-
ment of transplanted β-Gal-MSCs in vivo. Paraffin-fixed
sections were microwave-heated (750 W, three 5-minute
cycles) in 0.01 M citrate (pH 6.0) or 1-mM EDTA (pH 8.0)
solution. Immunostaining was performed with a 1:1,000 di-
lution of the anti-β-Galactosidase antibody (ab9361; AbcamInc, Cambridge, MA, USA) using the Dako-REAL,
Alkaline-Phosphatase/RED detection system (Dako,
Glostrup, Denmark). Hematoxylin was used for coun-
terstaining according to the manufacturer’s protocol.
The stained sections were scanned by the HistoFAXS
(TissueFAX plus; TissueGnostics, Vienna, Austria).
Collagen staining
The Sircol collagen assay (Biocolor Ltd., Belfast, UK), a
dye-binding method designed for the analysis of acid and
pepsin-soluble collagens, was used to detect the amounts of
collagenous protein in lung tissues. The stained tissue hom-
ogenate released Sircol red dyes by an alkali reagent (1 N
NaOH, Sigma-Aldrich) and measured by VERSAMax spec-
trophotometry (Molecular Devices). The amounts (μg) of
collagenous proteins in each tissue were determined by OD
at 550 nm.
Statistical analysis
Data are either shown as individual data points in a ver-
tical scatter dot plot, with a line to indicate the mean, or
as bar graphs showing mean ± standard deviation (SD).
Comparisons between two groups were analyzed using
the two-tailed Student’s t-test. For multiple comparisons,
one-way analysis of variance analysis was used, followed
by the Tukey’s post hoc test for analyzing parametric
data. All statistical analyses were performed using Graph
Pad Prism (GraphPad Software, Inc., San Diego, CA,
USA). *P < 0.05, **P < 0.01 and ***P < 0.001 are consid-
ered statistically significant.
Results
Hypoxic preconditioning upregulates expression of
cytoprotective and regenerative factors in mesenchymal
stem cells
To optimize hypoxic conditions for preconditioning
MSCs, the time course of hypoxia-inducible factor
(HIF)-1α expression during 48 hours exposure to a 1.5%
O2 concentration was followed. The mRNA expression
level of HIF-1α showed a gradual increase at 6 hours
and reached peak level at 12 hours of hypoxic exposure
(2.74 ± 0.2, peak expressed as relative gene expression
changes; Figure 1A). A peak protein expression level of
HIF-1α was observed after 24 hours of exposure
(Figure 1E). Results showed that expression of the
hypoxia marker, HIF-1α, was upregulated significantly
in hypoxia- compared with normoxia-treated MSCs
(Figure 1A). HIF-1α plays a predominant role in the up-
regulation of survival and anti-oxidant genes and also
growth factors [26,38]. To characterize the HP-MSCs, the
expression levels of representative cytoprotective and
regenerative factors were determined using quantitative
real-time RT-PCR and western blot analysis. Erythropoietin
receptor, one of the regulators of HIF-1α-mediated cell
Figure 1 Effects of hypoxic preconditioning on cytoprotective and regenerative gene expression in hypoxia-preconditioned mesenchymal stem cells.
Quantitative real-time RT-PCR was performed to examine the relative expression levels of mRNAs. (A) Hypoxia-induced factor (HIF)-1α in mesenchymal
stem cells (MSCs) after 6 to 24 hours exposure under 1.5% oxygen conditions. (B) The HIF-1α downstream target genes, erythropoietin receptor (EPOR)
and vascular endothelial growth factor (VEGF), (C) pro- and anti-apoptotic factors, B-cell lymphoma 2-associated X protein (BAX) and B-cell lymphoma 2
(Bcl-2), and (D) anti-oxidants, catalase (CAT) and heme oxygenase 1 (HO-1), in normoxia-preconditioned MSCs (NP-MSCs; 20% O2 for 24 hours) and
hypoxia-preconditioned MSCs (HP-MSCs; 1.5% O2 for 24 hours). (E) Western blot analysis was performed to detect the expression level of HIF-1α in MSCs
after 2 to 48 hours incubation under the 1.5% oxygen condition. (F) Comparison of protein levels of HGF, VEGF, and HO-1 in NP-MSCs (20% O2 for 24
hours) and HP-MSCs (1.5% O2 for 24 hours) in western blot analysis. Mouse β-actin was used as the normalization control. (A-D) Open and filled bars
indicate NP-MSCs and HP-MSCs, respectively. Values were normalized to β-actin and are expressed relative to the respective control group. *P < 0.05,
**P < 0.01, ***P < 0.001.
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0.15, expressed as relative gene expression changes;
Figure 1B). Moreover, the multifunctional cytoprotec-
tive gene, HGF, and the proangiogenic gene, VEGF (2.62± 0.04, expressed as relative gene expression changes),
were also significantly overexpressed in HP-MSCs
(Figure 1B). The anti-apoptotic gene, B-cell lymphoma
2(Bcl-2), was also significantly upregulated (1.61 ± 0.03,
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hypoxic conditions; however, there were no significant
differences in the expression of B-cell lymphoma 2-
associated X protein (BAX) between normoxic and
hypoxic cells (Figure 1C). Furthermore, low oxygen
tension also upregulated the levels of the anti-oxidant
genes, catalase (1.92 ± 0.05, expressed as relative gene
expression changes) and HO-1 (1.54 ± 0.05, expressed as
relative gene expression changes) in HP-MSCs (Figure 1D).
Upregulated expression of HGF, VEGF and HO-1 was fur-
ther confirmed in western blot analysis (Figure 1F).
Hypoxic preconditioning stabilizes the mitochondrial
membrane potential in mesenchymal stem cells
Mitochondria are critical oxygen sensors linked to various
protective effects, such as enhancement of antioxidantFigure 2 Hypoxic preconditioning promotes cell proliferation and decreases h
cells. (A) Mesenchymal stem cells (MSCs) were stained with 1 μM JC-10 for 30 m
wavelength emission of JC-10, most stained cells distributed at the double-posi
correct the bleed of the green (monomer) and red (aggregate) fluorescence sig
data. The gated region represented the higher mitochondrial membrane poten
of three independent normoxia-preconditioned MSCs (NP-MSCs) and hypoxia-p
of NP-MSCs and HP-MSCs was determined by an automated cell counter. (C) C
concentration for 1 hour as assessed by flow cytometric analysis with Annexin V
positive cells (dead cells population) are shown. (D) MTT assays of cell viability o
of NP-MSC- or HP-MSC-conditioned medium for 48 hours. *P < 0.05, **P < 0.01,defense, cell survival and anti-apoptosis [39,40]. To deter-
mine the mitochondrial functions in HP-MSCs in relation
to NP-MSCs, the mitochondrial membrane potential in
MSCs was assessed using membrane-permeant dual-
emission potential-sensitive JC-10 dye and flow cytometry
analysis. Dot plot revealed that all JC-10-stained cells dis-
tributed into the double-positive region (Figure 2A; left
panel). Due to the dual wavelength emission of JC-10,
electronic compensation was used to correct for spillage
of the green (monomer) and red (aggregate) fluorescence
signals into the FL2 and FL1 channels, respectively [41].
The compensated results showed a 14.8% higher red
fluorescence signal in HP-MSCs when compared with
that in NP-MSCs (approximately 5.9% higher red fluor-
escence signal), representing a 2.5-fold increment
(Figure 2A; right panel).ydrogen peroxide- or belomycin-induced cell death in mesenchymal stem
inutes, and were then analyzed by flow cytometry. Owing to the dual
tive region (top right quadrant). Electronic compensation was made to
nals into the FL2 and FL1 channels. Right column shows compensated
tial cell population. The histogram on the right shows the quantification
reconditioned MSCs (HP-MSCs) samples of JC-10 staining. (B) Cell number
ell viability of NP-MSCs and HP-MSCs treated with the indicated H2O2
/propidium iodide (PI) staining. Percentages of Annexin V/PI-double
f bleomycin-treated mouse lung epithelial cells (MLE-12) in the presence
differences between HP-MSCs and the NP-MSC controls.
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reduces hydrogen peroxide-induced cytotoxicity in
mesenchymal stem cells and attenuates bleomycin-induced
alveolar epithelial cell death
The effects of hypoxic culture on MSC proliferation and
expansion efficiency are dependent on the sources of
MSCs, oxygen concentration, seeding density and the cul-
turing duration of the MSCs [20]. MSCs cultured in hyp-
oxic conditions increased by about 40% in cell number
when compared to normoxic cells (cell number (×105) of
NP-MSCs = 4.50 ± 0.62, versus HP-MSCs = 6.27 ± 0.58;
P < 0.01; Figure 2B). The hypoxic conditions used showed
no adverse effects on cell viability (data not shown). To
study the effects of hypoxic preconditioning on H2O2-in-
duced cytotoxicity, HP-MSCs were cultured for 24 hours,
followed by exposure to H2O2 for 1 hour. Results showed
that H2O2 induced cell death in a dose-dependent man-
ner, as measured by annexin V/PI staining (1 μM H2O2
treatment with NP-MSCs (39.67 ± 3.49) versus HP-MSCs
(26.83 ± 2.62); 2 μM H2O2 treatment with NP-MSCs
(62.70 ± 1.82) versus HP-MSCs (51.95 ± 3.29); Figure 2C).
As anticipated, there were significant degrees of protec-
tion against H2O2-induced cell death in HP-MSCs com-
pared with NP-MSCs (Figure 2C). Mouse alveolar
epithelial cells (MLE-12) were further used to examine the
cytoprotective effects of paracrine factors secreted by
MSCs in attenuating BLM-induced cell death. MLE-12
cells were cultured in the presence of conditioned
medium (CM) from NP-MSCs or HP-MSCs while under
BLM treatment, followed by MTT assays. CM from HP-
MSC cultures was able to improve lung epithelial cell sur-
vival compared to the control and NP-MSC CM during
BLM treatment (58.70 ± 2.73 versus 69.27 ± 0.63, P < 0.01;
Figure 2D).
Hypoxia-preconditioned mesenchymal stem cell-conditioned
medium attenuates extracellular matrix production through
transforming growth factor-β1-mediated Akt signaling
Previous studies have shown that TGF-β1 induces synthe-
sis of ECM components, resulting in increased phosphor-
ylation of Akt and its downstream signaling in fibroblast
cells [42,43]. To assess the anti-fibrotic effects of MSCs,
the production of the ECM protein fibronectin and down-
stream signaling in the TGF-β1-stimulated MRC-5 fibro-
blasts were examined using an in vitro co-culture system
and treatment with CM. TGF-β1 treatment increased
both the fibronectin mRNA (3.57 ± 013, expressed as rela-
tive gene expression changes) and protein expression
levels in MRC-5 cells and also activated Akt signaling
(Figure 3). As anticipated, ECM synthesis was significantly
attenuated in both normoxic- and hypoxic-MSCs groups,
while HP-MSCs showed higher inhibitory effects for ECM
production than NP-MSCs (2.03 ± 0.01 after co-culture
with HP-MSCs versus 3.57 ± 0.13 (media control) and2.44 ± 0.08 (NP-MSCs), expressed as relative gene expres-
sion changes; Figure 3A). Western blot analysis also
showed that CM collected from both normoxic- and hyp-
oxic-MSCs downregulated the expression of phosphory-
lated AKT and fibronectin (Figure 3B).
Hence, we used two approaches to examine whether HP-
MSCs attenuated ECM production through HGF. Firstly,
genetic knock-down of HGF with short hairpins (shRNAs)
in MSCs was used, followed by the use of an in vitro co-
culture system to assess the anti-fibrotic effects. After 24
hours of co-culture, MSCs transfected with shRNA showed
about a 50% decrease in the HGF mRNA level compared
to cells transfected with the control scramble shRNA plas-
mid. Under hypoxic conditions, expression levels of HGF
were significantly decreased in MSCs transfected with
shRNA compared to the control group (data not shown).
On the other hand, knockdown of HGF also abrogated the
suppressive effects of HP-MSCs on TGF-β1-induced over-
expression of fibronectin (2.64 ± 0.07 after co-culture with
control media versus 1.68 ± 0.06 (HP-MSCs) and 2.29 ±
0.22 (HP-shHGF), expressed as relative gene expression
changes; Figure 3C). Secondly, pharmacological inhibition
of c-Met with its specific inhibitor, PHA-665752, to sup-
press HGF signaling in MRC-5 cells was also tested. Results
showed that ECM production significantly increased in the
MRC-5 cells treated with TGF-β1 plus PHA-665752. Al-
though treatment with HP-MSC CM obviously suppressed
expression of fibronectin, co-treatment with HP-MSC CM
and PHA-665752 significantly inhibited the suppressive ef-
fects (3.55 ± 0.04 after treatment with HP-MSC CM versus
4.61 ± 0.05 (control media) and 4.88 ± 0.07 (HP-MSC CM
plus PHA-665752), expressed as relative gene expression
changes; Figure 3D). The results indicated that paracrine
factors, such as HGF, derived from CM of HP-MSCs play a
crucial role for attenuation of ECM production.
Improvement of pulmonary respiratory functions of
hypoxia-preconditioned mesenchymal stem cell treatment
in the bleomycin-induced pulmonary fibrosis mouse model
To evaluate the therapeutic efficacy of HP-MSCs in the
BLM-induced pulmonary fibrosis mouse model, WBP was
used to monitor lung functions of the treated mice. The
respiratory parameter, in particular Penh, was measured
as a noninvasive index of BLM-induced airway dysfunc-
tion [44]. In the experiments, the Penh values showed a
two-fold increment at day 21 after BLM treatment com-
pared with the PBS control group (0.61 ± 0.06 versus 1.16
± 0.33, P < 0.05; Figure 4A). In addition, the BLM HP-
MSC group had the lowest Penh value which was approxi-
mately the same as the PBS control; however, the BLM
NP-MSC group showed no significant improvements in
lung function in the fibrosis animal model (0.70 ± 0.07 in
BLM HP-MSCs versus 1.19 ± 0.34 (BLM NP-MSCs) and
1.16 ± 0.33 (BLM control); Figure 4A). In addition,
Figure 3 Hypoxia-preconditioned mesenchymal stem cells attenuate extracellular matrix production through transforming growth factor-β1-mediated
Akt signaling. In the assessment of the anti-fibrotic effects of mesenchymal stem cells (MSCs), transforming growth factor (TGF)-β1-stimulated MRC-5
fibroblasts were used. (A) Co-culture experiments were performed in which mock control (Ctrl, culture medium only), TGF-β1 control, normoxia-
preconditioned MSCs (NP-MSCs) or hypoxia-preconditioned MSCs (HP-MSCs) were seeded in the upper chamber, and TGF-β1 (1 ng/ml)-treated MRC-5
fibroblast cells were seeded in the lower chamber. After 24 hours incubation, quantitative real-time RT-PCR was performed to examine the
fibronectin mRNA levels in MRC-5 cells. (B) Western blot analysis of fibronectin and phosphorylated Akt in TGF-β1-treated MRC-5 cells after
incubation with MSC-conditioned media (CM) for 24 hours. (C) Co-culture experiments were performed in which mock Ctrl, TGF-β1 Ctrl, HP-Ctrl
(hypoxia-pretreated MSCs transfected with control scramble short hairpin RNA (shRNA) plasmid) or HP-shHGF were seeded in the upper chamber, and
TGF-β1 (1 ng/ml)-treated MRC-5 fibroblast cells were seeded in the lower chamber. After 24 hours incubation, quantitative real-time RT-PCR was
performed to examine the fibronectin mRNA levels in MRC-5 cells. (D) MRC-5 cells were preincubated with or without PHA-665752 (1 μM) for 24 hours,
and then cells were treated with or without HP-MSC CM for 24 hours. Quantitative real-time RT-PCR was performed to examine changes in
the fibronectin mRNA levels in the MRC-5 cells. Values were normalized to the β-actin gene and are expressed relative to the control (Ctrl) group.
**P < 0.01, ***P < 0.001. HGF, hepatocyte growth factor.
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for 21 days showed a significant increment in the lung wet-
to-dry ratio, indicating the degree of pulmonary edema
caused by an inflammatory response in the lung. Likewise,
the BLM HP-MSC group showed a lower wet-to-dry ratio
than the BLM NP-MSC and BLM control groups at day 18
after stem cells transplantation (0.32 ± 0.05 in BLM HP-
MSC group versus 0.43 ± 0.05 (BLM NP-MSC) and 0.42 ±
0.10 (BLM control); Figure 4B) also indicating that trans-
plantation of HP-MSCs significantly reduced lung fluid
content caused by BLM treatment. Taken together, our re-
sults indicated that transplanted HP-MSCs showed bettertherapeutic effects and improved lung functions in mice
with BLM-induced pulmonary fibrosis.
Downregulated expression of inflammatory and fibrotic
factors in hypoxia-preconditioned mesenchymal stem
cell-transplanted bleomycin-induced pulmonary fibrosis
mouse model
To determine the effects of HP-MSCs on inflammation and
fibrosis in the BLM-induced pulmonary fibrosis model, ex-
pression levels of possible mediators that may be involved,
including pro-inflammatory cytokine and fibrotic factors,
were determined. The mRNA level of the inflammation-
Figure 4 Hypoxia-preconditioned mesenchymal stem cell transplantation improves long-term attenuation of bleomycin-induced airway constriction and
lung edema. (A) Pulmonary functions were evaluated as enhanced respiratory pause (Penh) values in animals that received normoxia-preconditioned
mesenchymal stem cells (NP-MSCs), hypoxia-preconditioned mesenchymal stem cells (HP-MSCs) or phosphate-buffered saline (PBS) for 18 days following
bleomycin (BLM) administration on day 3. Whole-body plethysmography was employed and Penh was used as a noninvasive index of airway dysfunction.
(B) After sacrificing the mice on day 21, the lung wet-to-dry weight ratio was determined to assess pulmonary edema. Each dot represents an individual
mouse with the mean shown for n ≥ 5 per group. *P < 0.05, **P < 0.01. Ctrl, control.
Lan et al. Stem Cell Research & Therapy  (2015) 6:97 Page 10 of 17mediating IL-6 was significantly upregulated 21 days after
BLM treatment compared with the PBS control group
(0.91 ± 0.32 versus 5.81 ± 4.01, P < 0.01; Figure 5A). On
the other hand, pro-IL-1β showed no significant upregula-
tion at the mRNA level, but the protein levels of the pre-
cursor and mature IL-1β were markedly overexpressed
(Figure 5B,C). However, there was a significant reduction in
the expression of these inflammatory mediators in the HP-
MSC transplantation group (IL-6 mRNA level: 0.69 ± 0.44
in BLM HP-MSC group versus 4.65 ± 4.04 (BLM NP-
MSC) and 5.81 ± 4.01 (BLM control); pro-IL-1β mRNA
level: 0.41 ± 0.20 in BLM HP-MSC group versus 0.86 ±
0.30 (BLM NP-MSCs) and 1.02 ± 0.30 (BLM control);
Figure 5A-C). Interestingly, there was no discernible differ-
ence in the levels of inflammation between the BLM NP-
MSCs and BLM control groups (Figure 5A-C). Further-
more, expression of two factors mediating fibrosis, namely
collagen type III and connective tissue growth factor
(CTGF), was significantly upregulated at day 21 post-BLM
treatment, but expression of collagen type III and CTGF
was clearly reduced on HP-MSC transplantation (collagen
type III mRNA level: 1.04 ± 0.72 in BLM HP-MSC group
versus 3.62 ± 2.24 (BLM NP-MSC) and 5.40 ± 1.90 (BLM
control); CTGF mRNA level: 0.66 ± 0.58 in BLM HP-MSC
group versus 3.86 ± 3.70 (BLM NP-MSC) and 8.58 ± 7.91
(BLM control); Figure 6A,B). Moreover, there was clearly
collagen deposition after BLM treatment, but only low col-
lagen content could be detected in the HP-MSC trans-
planted mice which was comparable to the normal level
(8.87 ± 7.20 μg/mg wet lung tissue in BLM HP-MSC group
versus 20.17 ± 15.36 (BLM NP-MSCs) and 28.48 ± 3.06
(BLM control) and 8.02 ± 4.26 (PBS control); Figure 6C).
Noting the downregulation of inflammatory and fibrotic
mediators, other possible cytoprotective mediators were
further investigated by examining the expression levels ofHGF in whole-lung tissues by western blot analysis. HGF
showed decreased levels in the BLM only and MSC-treated
mice, but was overexpressed in the HP-MSC-transplanted
mice (Figure 6D). Taken together, transplantation of HP-
MSCs exerted better inhibitory effects on upregulating pro-
inflammatory and fibrotic factors and on inducing the accu-
mulation of collagen than in the BLM NP-MSC group (Fig-
ures 5 and 6).
Hypoxia-preconditioned mesenchymal stem cell
transplantation alleviates histological changes in the
lungs of the bleomycin-induced pulmonary fibrosis
mouse model
The lung histopathologic sections from each experimental
group at day 18 after stem cell transplantation are shown in
Figure 7. There was no obvious lesion or inflammatory
infiltration in the lung of the PBS control group (Figure 7A).
In the BLM-only group, hematoxylin and eosin and
Masson’s trichrome staining showed that the pulmonary
alveolus cavities were obviously decreased in size, the alveo-
lar wall was thickened, and there was accumulation of in-
flammatory cells (Figure 7B,F). Lungs from MSC-engrafted
mice showed thinner alveolar wall, but with accumulation
of inflammatory cells (Figure 7C,G). On the other hand,
lung tissues of HP-MSC-transplanted mice showed a
significant reduction of the alveolar wall thickness and
accumulation of collagen in the lung interstitium
(Figure 7D,H). Quantitative analysis was performed
using the Ashcroft score (2.13 ± 0.81 (BLM NP-MSC)
versus 3.90 ± 0.57 (BLM NP-MSC) and 5.0 ± 1.15 (BLM
control), P < 0.001; Figure 7Q). To determine whether
engrafted HP-MSCs survived and adopted in the dam-
aged lungs at day 7 and 21 after BLM treatment, we
intratracheally administered LacZ reporter-transduced
MSCs (β-Gal-MSCs) into the BLM-induced pulmonary
Figure 5 Hypoxia-preconditioned mesenchymal stem cell transplantation downregulates expression of inflammatory factors in the bleomycin-
induced pulmonary fibrosis mouse model. Quantitative real-time RT-PCR was performed to analyze the expression of inflammatory factors (A)
interleukin (IL)-6 and (B) pro-IL-1β in the lung tissues of animals that received normoxia-preconditioned mesenchymal stem cells (NP-MSCs),
hypoxia-preconditioned mesenchymal stem cells (HP-MSCs) or phosphate-buffered saline (PBS) for 18 days following bleomycin (BLM) administra-
tion on day 3. Values are normalized to the GAPDH values and expressed relative to the PBS group. *P < 0.05, **P < 0.01. Each dot represents an
individual mouse with the mean shown for n > 5 per group. (C) Western blot analysis of pro-IL-1β and IL-1β in whole lung tissues from each
group. Ctrl, control.
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immunohistochemical staining and quantitative real-time
RT-PCR. At day 4 after stem cell engraftment (Figure 7I-
L,R), there were no LacZ-labeled cells or LacZ mRNA ob-
served in lung tissue sections of either the PBS or BLM
control group. However, an approximately six- to eight-
fold increment of LacZ mRNA was detected and numer-
ous LacZ-labeled cells were observed to be distributed
around the bronchi in both the NP-MSC and HP-MSC
treatment groups (Figure 7K,L,R). As anticipated, at day 18
after stem cell transplantation (Figure 7M-P,S), there were
no LacZ-labeled cells or LacZ mRNA observed in lung tis-
sue sections of either the normal, injured or NP-MSC
group. However, an approximately three-fold increment of
LacZ mRNA was detected and numerous LacZ-labeled
cells were observed and distributed around the bronchi in
the HP-MSC treatment group (Figure 7P,S).
Our data indicated that hypoxic preconditioning en-
hanced the survival rate of engrafted MSCs, exerted better
therapeutic effects and improved lung functions in BLM-
induced pulmonary fibrotic mice.
Discussion
Accumulating evidence suggests that stem cell-based ther-
apies may be used for lung regeneration and modulation of
inflammatory and fibrotic processes [7]. Ortiz and col-
leagues [45] first reported that systemically engrafted MSCspossessed the ability to ameliorate fibrotic effects in mice
challenged with BLM. Other reports have shown that mul-
tiple mechanisms are probably involved in the engrafted
MSCs leading to improved outcome in animal models with
pulmonary fibrosis [7,46]. In this work, we are the first to
demonstrate that engraftment of HP-MSCs rendered better
therapeutic effects than untreated MSCs in a BLM-induced
pulmonary fibrosis animal model. Hypoxic preconditioning
upregulated cytoprotective and regenerative genes, stabi-
lized mitochondrial membrane potentials, promoted cell
proliferation and acted against H2O2-induced cell death in
the treated MSCs. Moreover, HP-MSCs attenuated BLM-
induced cell apoptosis and ECM production through TGF-
β1-mediated Akt signaling via paracrine effects. HP-MSC
engraftment improved lung functions, reduced lung edema
and the levels of pro-inflammatory and fibrotic factors.
Although recent studies indicated that both local
(intratracheal) and systemic (intravenous or intraperito-
neal) infusion may be effective in attenuating lung
injury, the optimal route of delivery remains unclear
[47]. On the other hand, systemic administration of
MSCs showed some difficult conditions for application
to the clinical setting, such as the recipient requiring
total body irradiation to promote stem cell engraftment
[10]. Alternatively, considering the advantages of local
administration to target the lung tissue, several recent
studies reported that a lower dosage of stem cells are
Figure 6 Hypoxia-preconditioned mesenchymal stem cell transplantation reduces pulmonary collagen deposition and fibrosis-related genes expression in
the bleomycin-induced pulmonary fibrosis mouse model. (A,B) Quantitative real-time RT-PCR was performed to analyze the expression of fibrotic indicators
(A) connective tissue growth factor (CTGF) and (B) collagen type III (Col III) in the lung tissues of mice that received normoxia-preconditioned mesenchymal
stem cells (NP-MSCs), hypoxia-preconditioned mesenchymal stem cells (HP-MSCs) or phosphate-buffered saline (PBS) for 18 days following bleomycin (BLM)
administration on day 3. Values are normalized to the GAPDH gene and are expressed relative to the PBS group. (C) Total collagen content of whole lung
tissues from each group was determined by Sircol Collagen Assay. *P < 0.05, ***P < 0.001; n ≥ 5. (D)Western blot analysis of hepatocyte growth factor (HGF)
in whole lung tissues from each group.
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showed more effective airway regeneration [50,51] com-
pared with the intravenous route.
Although MSC-based cell therapy has shown great po-
tential in cell repair, the therapeutic effects of MSC-based
approaches have met a bottleneck following transplant-
ation. Leblond and colleagues [10] reported that a large
number of the engrafted cells were trapped in the damaged
lungs during short-term treatment. Less than 5% of im-
planted cells remained detectable in the injured lungs 7
days after transplantation [52]. Our results also showed that
the number of engrafted MSCs dramatically decreased with
time after transplantation (data not shown). To resolve
poor therapeutic efficacy of long-term MSC transplant-
ation, recent studies have proposed various strategies aim-
ing to precondition implanted MSCs by sublethal physical
and chemical stresses or genetic and pharmacological
stimuli to increase tolerance of the transplanted cells to
withstand the severe microenvironment of the trans-
planted sites [11-13,53].
Murry and colleagues [54] first described the phe-
nomenon termed “ischemic preconditioning” which at-
tenuated myocardium damage induced by ischemia.
Our data suggest that hypoxic preconditioning may be a
better solution for the transplanted cells to adapt to lowoxygen tension microenvironment, or in organs with
lesions, through systematically activating and altering a
series of cellular responses [55-57]. Many of these alter-
ations, including improved growth kinetics, homing abil-
ity, survival, regenerative, and genetic stability of the
implanted cells are characterized by upregulation of cyto-
protective genes HIF-1α, erythropoietin receptor, B-cell
lymphoma 2, HGF and VEGF [21,40,58-60]. In addition,
these cytoprotective factors exert both autocrine and para-
crine effects [61]. In agreement with previous studies, our
in vitro studies showed that HP-MSCs upregulated ex-
pression of cytoprotective genes (Figure 1). The reason
why 1.5% O2 concentration was chosen in this study was
that 1.5% mimics the low oxygen concentration (1 to 2%)
naturally encountered by MSCs in their bone marrow
niche [62-64]. It has been reported that short-term (24
hour) exposure of MSCs to hypoxia at 1.5% O2 stabilizes
the HIF-1 protein, and clearly promotes proliferation, cell
cycle progression and migration [65]. The viability of
MSCs was not adversely affected by 24 hours of hypoxia
at 1.5% O2 (data not shown). The mRNA expression level
of HIF-1α reached the peak level at 12 hours of hypoxic
exposure (Figure 1A), whereas the HIF-1α protein level
peaked after 24 hours of exposure (Figure 1E). On the
other hand, western blot analyses showed that hypoxic
Figure 7 Hypoxia-preconditioned mesenchymal stem cell transplantation reduces fibrotic histopathologic changes in the bleomycin-induced pulmonary
fibrosis mouse model. Representative images at day 21 of (A-D) hematoxylin and eosin and (E-H) Masson’s trichrome-stained histological sections from each
group. Immunohistochemistry staining was performed to observe the distribution of LacZ in lung tissues at (I-L) day 7 and (M-P) day 21 of mesenchymal
stem cell (MSC)-treated mice. (A,E,I,M) Phosphate-buffered saline (PBS) control, (B,F,J,N) bleomycin (BLM) + PBS, (C,G,K,O) BLM + normoxia-preconditioned
MSCs (NP-MSCs), (D,H,L,P) BLM + hypoxia-preconditioned MSCs (HP-MSCs). Scale bar = 100 μm. Solid arrows around the bronchi indicate LacZ-positive cells
(brown spots). (Q) The fibrotic changes in the lung were quantified by using Ashcroft scores on day 21 after administration, ranging from 0 (normal lung)
to 8 (complete fibrosis). Quantitative real-time RT-PCR was performed to detect the expression of LacZ in the lung tissues of mice that received NP-MSCs,
HP-MSCs or PBS on (R) day 4 and (S) day 18 following BLM administration on day 3. Values are normalized to the GAPDH values and expressed relative to
the PBS group. *P < 0.05, ***P < 0.001. Each dot represents an individual mouse with the mean shown for n ≥ 3 per group. Ctrl, control.
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of the cytoprotective proteins (Figure 1), reaching max-
imum at 24 hours after hypoxic preconditioning.
The strategies of HP-MSC transplantation have shown
potential benefits in several experimental disease models in
acute kidney injury [30] and ischemic diseases [25,27,60,66].
Studies showed that therapeutic effects were improved on
hypoxic treatment due to activation of HIF-1α followed by
upregulation of growth factors and downregulation of pro-
inflammatory cytokines and chemokines in hypoxic MSCs
[59]. Such events positively support HP-MSCs to overcome
limitations and circumvent hindrances in cell-based therapy
[55]. Here, we found that intratracheal instillation of HP-
MSCs provided better therapeutic effects than untreated
MSCs after BLM exposure, and protected lung tissues from
injuries by improving the pulmonary functions (Figure 4)
and reducing the extent of inflammation (Figure 5) and fi-
brosis (Figure 6).
Mounting evidence has shown that BLM as a chemother-
apeutic agent has undesirable side-effects in inducing lung
injuries and triggering apoptosis of alveolar epithelial cells
[67]. In addition, either BLM or downstream TGF-β1 may
induce ECM synthesis, and ECM deposition is mediated
through Akt signaling in fibroblasts [43]. Hence, dysregula-
tion of intercellular cross-talk between alveolar epithelia and
fibroblasts is a critical event in the fibrosis process. The net
balance is disturbed when alveolar epithelial cells die and
then factors such as TGF-β1 shift the balance toward en-
hancement of fibroblast proliferation and ECM production
[68]. Our study showed that HP-MSCs possessed better
cytoprotective abilities to resist stimuli-induced alveolar epi-
thelial cell death (Figure 2B,C) and to attenuate Akt-
mediated ECM production in fibroblast cells through para-
crine effects (Figure 3). Consistent with other studies, trans-
plantated MSCs site-specifically migrate into damaged
alveolar epithelial cells, and reduced alveolar epithelial cell
apoptosis [45,69], resulting in the differentiation of MSCs
into alveolar epithelial cells [70] through paracrine mecha-
nisms [71]. Hence, transplantation of HP-MSCs inhibited
production of pro-inflammatory mediators (Figure 5), at-
tenuated ECM deposition (Figure 6C) and reduced alveolar
wall thickness (Figure 7D) in the fibrosis lung model.
Many reports have shown some benefits from using
MSCs to attenuate inflammatory response and fibrosis.
However, the therapeutic efficacy may be affected by the
transplanted cell number, cell ages, timing of transplant-
ation, and treatment period [72]. Most studies assessed
the therapeutic effects at day 7 or day 14 after BLM treat-
ment, but only a few studies showed the longer period of
treatment effects. Aguilar and colleagues noted that deliv-
ery of MSCs at the time of BLM injury and 3 days later,
the end point of their experiments found that MSCs
showed no effect in attenuating the ECM deposition and
histological damage [73]. Moodley and colleagues noted thatthere was no change in aberrant lung collagen deposition in
the MSC treatment group at day 21 after BLM injury [74].
Moreover, Cargnoni and colleagues noted that transplant-
ation of MSCs slightly modulated lung inflammation during
long-term treatment [75]. Similar results were shown in our
study; NP-MSC treatment showed slight suppression of
ECM deposition and no effect on inflammatory response at
day 21 after BLM treatment. Therefore, HP-MSCs were
more effective at reducing inflammatory and ECM produc-
tion (Figures 4, 5 and 6).
Recent studies have demonstrated that HGF plays a key
role in preventing fibrosis or scar formation after injuries
[76,77]. Moreover, HGF exerts multiple protective effects on
injured tissues via mitogenic, motogenic, anti-apoptosis,
and anti-inflammatory and anti-fibrogenic signals [78-82].
Reports also showed that TGF-β1-induced fibrosis could
be prevented by treatment with HGF through inhibiting
myofibroblast differentiation [83,84] and ECM production
[85-87]. In agreement with this reported evidence, the re-
generative factor HGF was significantly upregulated in the
HP-MSC-treated fibrotic lungs in the present study
(Figure 6D).
Conclusions
In summary, we report here that transplantation of HP-
MSCs improves pulmonary functions and reduces inflam-
matory and fibrotic mediators in a BLM-induced pulmonary
fibrosis model. The upregulation of HGF might play a key
role in mediating the therapeutic effects of transplanted HP-
MSCs.
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